These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 15310454)

  • 41. Smaller protein, larger therapeutic potential: PPM1D as a new therapeutic target in brainstem glioma.
    Reitman ZJ
    Pharmacogenomics; 2014 Sep; 15(13):1639-41. PubMed ID: 25410889
    [No Abstract]   [Full Text] [Related]  

  • 42. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints.
    Lu X; Nannenga B; Donehower LA
    Genes Dev; 2005 May; 19(10):1162-74. PubMed ID: 15870257
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53.
    Pärssinen J; Alarmo EL; Karhu R; Kallioniemi A
    Cancer Genet Cytogenet; 2008 Apr; 182(1):33-9. PubMed ID: 18328948
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PPM1D is a potential target for 17q gain in neuroblastoma.
    Saito-Ohara F; Imoto I; Inoue J; Hosoi H; Nakagawara A; Sugimoto T; Inazawa J
    Cancer Res; 2003 Apr; 63(8):1876-83. PubMed ID: 12702577
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.
    Efferson CL; Winkelmann CT; Ware C; Sullivan T; Giampaoli S; Tammam J; Patel S; Mesiti G; Reilly JF; Gibson RE; Buser C; Yeatman T; Coppola D; Winter C; Clark EA; Draetta GF; Strack PR; Majumder PK
    Cancer Res; 2010 Mar; 70(6):2476-84. PubMed ID: 20197467
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of differentially expressed genes after PPM1D silencing in breast cancer.
    Pärssinen J; Alarmo EL; Khan S; Karhu R; Vihinen M; Kallioniemi A
    Cancer Lett; 2008 Jan; 259(1):61-70. PubMed ID: 17977650
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
    Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
    Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetic variants and mutations of PPM1D control the response to DNA damage.
    Dudgeon C; Shreeram S; Tanoue K; Mazur SJ; Sayadi A; Robinson RC; Appella E; Bulavin DV
    Cell Cycle; 2013 Aug; 12(16):2656-64. PubMed ID: 23907125
    [TBL] [Abstract][Full Text] [Related]  

  • 49.
    Milosevic J; Treis D; Fransson S; Gallo-Oller G; Sveinbjörnsson B; Eissler N; Tanino K; Sakaguchi K; Martinsson T; Wickström M; Kogner P; Johnsen JI
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885154
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D.
    Rayter S; Elliott R; Travers J; Rowlands MG; Richardson TB; Boxall K; Jones K; Linardopoulos S; Workman P; Aherne W; Lord CJ; Ashworth A
    Oncogene; 2008 Feb; 27(8):1036-44. PubMed ID: 17700519
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Wip-ing out cancer.
    Bernards R
    Nat Genet; 2004 Apr; 36(4):319-20. PubMed ID: 15054481
    [No Abstract]   [Full Text] [Related]  

  • 52. The crucial role of a phosphatase in insulin resistance and obesity.
    Shalev A
    Eur J Endocrinol; 1999 Oct; 141(4):323-4. PubMed ID: 10526242
    [No Abstract]   [Full Text] [Related]  

  • 53. [Research progress of feature and function of mucins in breast cancer].
    Li X; Liu F; Fu L
    Zhonghua Bing Li Xue Za Zhi; 2015 Mar; 44(3):221-4. PubMed ID: 26268765
    [No Abstract]   [Full Text] [Related]  

  • 54.
    Akamandisa MP; Nahta R; Castellino RC
    Oncoscience; 2016; 3(7-8):186-187. PubMed ID: 27713908
    [No Abstract]   [Full Text] [Related]  

  • 55. MiR-145-5p Inhibits the Invasion of Prostate Cancer and Induces Apoptosis by Inhibiting WIP1.
    Sun J; Deng L; Gong Y
    J Oncol; 2021; 2021():4412705. PubMed ID: 34899906
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metal dependent protein phosphatase PPM family in cardiac health and diseases.
    Gao C; Cao N; Wang Y
    Cell Signal; 2021 Sep; 85():110061. PubMed ID: 34091011
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Silencing of PPM1D inhibits cell proliferation and invasion through the p38 MAPK and p53 signaling pathway in papillary thyroid carcinoma.
    Lu ZW; Wen D; Wei WJ; Han LT; Xiang J; Wang YL; Wang Y; Liao T; Ji QH
    Oncol Rep; 2020 Mar; 43(3):783-794. PubMed ID: 31922231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. WIP1 phosphatase as pharmacological target in cancer therapy.
    Pecháčková S; Burdová K; Macurek L
    J Mol Med (Berl); 2017 Jun; 95(6):589-599. PubMed ID: 28439615
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phosphatase Wip1 in Immunity: An Overview and Update.
    Shen XF; Zhao Y; Jiang JP; Guan WX; Du JF
    Front Immunol; 2017; 8():8. PubMed ID: 28144241
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel mathematical model of ATM/p53/NF- κB pathways points to the importance of the DDR switch-off mechanisms.
    Jonak K; Kurpas M; Szoltysek K; Janus P; Abramowicz A; Puszynski K
    BMC Syst Biol; 2016 Aug; 10(1):75. PubMed ID: 27526774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.